Lantheus Holdings (NASDAQ: LNTH) and Biocept (NASDAQ:BIOC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitabiliy, dividends and earnings.

Valuation & Earnings

This table compares Lantheus Holdings and Biocept’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Lantheus Holdings $317.61 million 2.02 $75.23 million $0.72 23.89
Biocept $4.68 million 7.39 -$17.28 million ($1.65) -0.79

Lantheus Holdings has higher revenue and earnings than Biocept. Biocept is trading at a lower price-to-earnings ratio than Lantheus Holdings, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lantheus Holdings and Biocept’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lantheus Holdings 8.44% -37.47% 15.16%
Biocept -383.29% -1,177.51% -204.76%

Insider and Institutional Ownership

65.9% of Lantheus Holdings shares are held by institutional investors. Comparatively, 15.8% of Biocept shares are held by institutional investors. 2.3% of Lantheus Holdings shares are held by company insiders. Comparatively, 7.7% of Biocept shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Lantheus Holdings has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Biocept has a beta of 3.01, suggesting that its share price is 201% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Lantheus Holdings and Biocept, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus Holdings 0 1 3 0 2.75
Biocept 0 0 3 0 3.00

Lantheus Holdings currently has a consensus target price of $18.75, suggesting a potential upside of 9.01%. Biocept has a consensus target price of $2.50, suggesting a potential upside of 92.31%. Given Biocept’s stronger consensus rating and higher possible upside, analysts plainly believe Biocept is more favorable than Lantheus Holdings.

Summary

Lantheus Holdings beats Biocept on 7 of the 12 factors compared between the two stocks.

Lantheus Holdings Company Profile

Lantheus Holdings, Inc. is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging. It operates in two segments: U.S. Segment and International Segment. The U.S. Segment produces and markets its medical imaging agents and products throughout the United States. In the United States, it sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. The International Segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. Its portfolio of nine commercial products is diversified across a range of imaging modalities. Its products include an ultrasound contrast agent and medical radiopharmaceuticals.

Biocept Company Profile

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.